NEW YORK CITY (dpa-AFX) - Tuesday, Pfizer Inc. (PFE) revealed positive
immunogenicity and safety results from the ongoing pivotal Phase 3 clinical
trial of Abrysvo vaccine.

The MONeT trial assessed the effectiveness of its respiratory syncytial virus or
RSV vaccine Abrysvo against a placebo in adults aged 18 to 59.

The study successfully met its co-primary immunogenicity and primary safety
goals, with participants experiencing at least a four-fold increase in serum
neutralizing titers for RSV-A and RSV-B one month after receiving Abrysvo
compared to before vaccination.

The company stated that the vaccine was well-received and showed an immune
response comparable to that of adults aged 60 and above, for whom the vaccine is
already approved.

Pfizer plans to present the trial findings to request expanded approval of the
vaccine to extend the age range from the current indication of 18 years and
above.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX